Idiopathic pulmonary fibrosis: Pathophysiology, cellular signaling, diagnostic and therapeutic approaches

Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, 183, 788, 10.1164/rccm.2009-040GL King, 2011, Idiopathic pulmonary fibrosis, Lancet, 378, 1949, 10.1016/S0140-6736(11)60052-4 Hutchinson, 2015, Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review, Eur Respir J, 46, 795, 10.1183/09031936.00185114 Hopkins, 2016, Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada, Eur Respir J, 48, 187, 10.1183/13993003.01504-2015 Gross, 2001, Idiopathic pulmonary fibrosis, N Engl J Med, 345, 517, 10.1056/NEJMra003200 Richeldi, 2017, Idiopathic pulmonary fibrosis, Lancet, 389, 1941, 10.1016/S0140-6736(17)30866-8 Martinez, 2017, Idiopathic pulmonary fibrosis, Nat Rev Dis Primers, 3, 1, 10.1038/nrdp.2017.74 Yount, 2016, Health-related quality of life in patients with idiopathic pulmonary fibrosis, Lung, 194, 227, 10.1007/s00408-016-9850-y Wu, 2017, Idiopathic pulmonary fibrosis: what is the best treatment, Barcelona Respir Netw, 3, 86 Kasuya, 2021, Pathophysiological roles of stress-activated protein kinases in pulmonary fibrosis, Int J Mol Sci, 22, 6041, 10.3390/ijms22116041 Barratt, 2018, Idiopathic pulmonary fibrosis (IPF): an overview, J Clin Med, 7, 201, 10.3390/jcm7080201 Ley, 2013, Epidemiology of idiopathic pulmonary fibrosis, Clin Epidemiol, 483, 10.2147/CLEP.S54815 Mathai, 2016, Pulmonary fibrosis in the era of stratified medicine, Thorax, 71, 1154, 10.1136/thoraxjnl-2016-209172 Wolters, 2014, Pathogenesis of idiopathic pulmonary fibrosis, Annu Rev Pathol, 9, 157, 10.1146/annurev-pathol-012513-104706 Selman, 2014, Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model, Am J Respir Crit Care Med, 189, 1161, 10.1164/rccm.201312-2221PP Selman, 2016, Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis, Eur Respir J, 48, 538, 10.1183/13993003.00398-2016 Lederer, 2018, Idiopathic pulmonary fibrosis, N Engl J Med, 378, 1811, 10.1056/NEJMra1705751 Hamanaka, 2021, Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism, FEBS J, 288, 6331, 10.1111/febs.15693 Massagué, 2012, TGFβ signalling in context, Nat Rev Mol Cell Biol, 13, 616, 10.1038/nrm3434 Shi, 2003, Mechanisms of TGF-β signaling from cell membrane to the nucleus, Cell, 113, 685, 10.1016/S0092-8674(03)00432-X Hanafusa, 1999, Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression, J Biol Chem, 274, 27161, 10.1074/jbc.274.38.27161 Hocevar, 1999, TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway, EMBO J, 18, 1345, 10.1093/emboj/18.5.1345 Yan, 1994, Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells, J Biol Chem, 269, 13231, 10.1016/S0021-9258(17)36823-0 Lamouille, 2007, Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway, J Cell Biol, 178, 437, 10.1083/jcb.200611146 Seay, 2005, Transforming growth factor-β-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent, J Pharmacol Exp Ther, 315, 1005, 10.1124/jpet.105.091249 Derynck, 2003, Smad-dependent and Smad-independent pathways in TGF-β family signalling, Nature, 425, 577, 10.1038/nature02006 Xiao, 2012, TGF-beta 1 induced fibroblast proliferation is mediated by the FGF-2/ERK pathway, Front Biosci (Landmark Ed), 17, 2667, 10.2741/4077 Deng, 2015, Platelet-derived growth factor and transforming growth factor β1 regulate ARDS-associated lung fibrosis through distinct signaling pathways, Cell Physiol Biochem, 36, 937, 10.1159/000430268 Lagares, 2012, Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation, Arthritis Rheum, 64, 1653, 10.1002/art.33482 Takabe, 2008, “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets, Pharmacol Rev, 60, 181, 10.1124/pr.107.07113 Chen, 2014, The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension, Am J Respir Crit Care Med, 190, 1032, 10.1164/rccm.201401-0121OC Goodwin J, Choi H, Hsieh M-h, Neugent ML, Ahn J-M, Hayenga HN, et al. Targeting hypoxia-inducible factor-1α/pyruvate dehydrogenase kinase 1 axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis. Am J Respiratory Cell Mol Biol 2018; 58: 216–31. Kim, 2013, ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation, Am J Pathol, 183, 1758, 10.1016/j.ajpath.2013.08.014 Frödin, 1999, Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction, Mol Cell Endocrinol, 151, 65, 10.1016/S0303-7207(99)00061-1 Knipe, 2015, The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis, Pharmacol Rev, 67, 103, 10.1124/pr.114.009381 Zhou, 2013, Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis, J Clin Invest, 123, 1096, 10.1172/JCI66700 Schofield, 2013, Rho-associated coiled-coil kinase (ROCK) signaling and disease, Crit Rev Biochem Mol Biol, 48, 301, 10.3109/10409238.2013.786671 Yoshida, 2002, MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis, J Pathol: A J Pathol Soc Great Britain Ireland, 198, 388, 10.1002/path.1208 Alcorn, 2009, c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis, Am J Respir Cell Mol Biol, 40, 422, 10.1165/rcmb.2008-0174OC van der Velden, 2020, Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models, PLoS One, 15, e0226904, 10.1371/journal.pone.0226904 Bennett, 2017, CC-90001, a second generation Jun N-terminal kinase (JNK) inhibitor for the treatment of idiopathic pulmonary fibrosis. C38 Understanding Therapeutics in IPF, Am Thoracic Soc, p. A5409-A van der Velden, 2016, JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers, Clin Transl Med, 5, 1, 10.1186/s40169-016-0117-2 Thannickal VJ, Lee D, White ES, Cui Z, Larios JM, Chacon R, et al. Myofibroblast differentiation by TGF-b1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase; 2003. Horowitz, 2007, Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblasts, Cell Signal, 19, 761, 10.1016/j.cellsig.2006.10.001 Horowitz, 2004, Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor, J Biol Chem, 279, 1359, 10.1074/jbc.M306248200 Fernandez, 2012, The impact of TGF-β on lung fibrosis: from targeting to biomarkers, Proc Am Thorac Soc, 9, 111, 10.1513/pats.201203-023AW Upagupta, 2018, Matrix abnormalities in pulmonary fibrosis, Eur Respir Rev, 27, 10.1183/16000617.0033-2018 Hirata, 2017, Post-translational modifications of the TAK1-TAB complex, Int J Mol Sci, 18, 205, 10.3390/ijms18010205 Xu, 2021, TAK1-TABs complex: a central signalosome in inflammatory responses, Front Immunol, 3208 Shakeel, 2021, Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications, J Drug Target, 29, 168, 10.1080/1061186X.2020.1818760 Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N Engl J Med, 370, 2071, 10.1056/NEJMoa1402584 King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, 370, 2083, 10.1056/NEJMoa1402582 Noble, 2011, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, 377, 1760, 10.1016/S0140-6736(11)60405-4 Noth, 2012, A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 186, 88, 10.1164/rccm.201202-0314OC Raghu, 2013, Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial, Ann Intern Med, 158, 641, 10.7326/0003-4819-158-9-201305070-00003 Prednisone, 2012, and N-acetylcysteine for pulmonary fibrosis, N Engl J Med, 366, 1968, 10.1056/NEJMoa1113354 Malouf, 2011, An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis, Respirology, 16, 776, 10.1111/j.1440-1843.2011.01955.x Daniels, 2010, Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results, Am J Respir Crit Care Med, 181, 604, 10.1164/rccm.200906-0964OC King, 2011, BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 184, 92, 10.1164/rccm.201011-1874OC Network, 2014, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, N Engl J Med, 370, 2093, 10.1056/NEJMoa1401739 Network, 2010, A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis, N Engl J Med, 363, 620, 10.1056/NEJMoa1002110 Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J, Group MS. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respiratory J 2013; 42: 1622-32. Richeldi, 2011, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N Engl J Med, 365, 1079, 10.1056/NEJMoa1103690 Hilberg, 2008, BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy, Cancer Res, 68, 4774, 10.1158/0008-5472.CAN-07-6307 Hostettler, 2014, Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis, Respir Res, 15, 1, 10.1186/s12931-014-0157-3 Sato, 2014, A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Effect Of Nintedanib (bibf1120) On Fibrocyte-Induced Fibroblast Activation, Am J Respir Crit Care Med, 189, 1 Schuett, 2015, The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF, Eur Respiratory Soc Wollin, 2014, Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis, J Pharmacol Exp Ther, 349, 209, 10.1124/jpet.113.208223 Wollin, 2015, Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis, Eur Respir J, 45, 1434, 10.1183/09031936.00174914 Morizumi, 2016, Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity, Eur Respiratory Soc Wollin L, Schuett J, Ostermann A, Herrmann F. The effect of nintedanib on platelet derived growth factor-stimulated contraction of human primary lung fibroblasts. A73 LUNG FIBROSIS: NEW DIRECTIONS TO INFORM THE FUTURE: American Thoracic Society; 2016. p. A2384-A. Tandon K, Herrmann F, Ayaub E, Parthasarathy P, Ackermann M, Inman MD, et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. A72 MECHANISMS DRIVING FIBROSIS: American Thoracic Society; 2017. p. A2397-A. Ackermann, 2017, Effects of nintedanib on the microvascular architecture in a lung fibrosis model, Angiogenesis, 20, 359, 10.1007/s10456-017-9543-z Wermuth, 2015, The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases, Clin Transl Med, 4, 1, 10.1186/s40169-015-0047-4 Terzyan, 2019, Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib, J Biol Chem, 294, 10428, 10.1074/jbc.RA119.007682 He, 2022, Identification and validation of aging-related genes in idiopathic pulmonary fibrosis, Front Genet, 13 Conte, 2014, Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts, Eur J Pharm Sci, 58, 13, 10.1016/j.ejps.2014.02.014 Lehtonen, 2016, Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis, Respir Res, 17, 1, 10.1186/s12931-016-0328-5 Nakayama, 2008, Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts, Life Sci, 82, 210, 10.1016/j.lfs.2007.11.003 Inomata, 2014, Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis, Respir Res, 15, 1, 10.1186/1465-9921-15-16 Kakugawa, 2004, Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis, Eur Respir J, 24, 57, 10.1183/09031936.04.00120803 Oku, 2008, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis, Eur J Pharmacol, 590, 400, 10.1016/j.ejphar.2008.06.046 Kolb, 2017, Therapeutic targets in idiopathic pulmonary fibrosis, Respir Med, 131, 49, 10.1016/j.rmed.2017.07.062 Shao, 2008, Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation, J Leukoc Biol, 83, 1323, 10.1189/jlb.1107782 Murray, 2014, Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model, Am J Respir Cell Mol Biol, 50, 985, 10.1165/rcmb.2013-0342OC Kihara, 2015, Lysophospholipid receptors in drug discovery, Exp Cell Res, 333, 171, 10.1016/j.yexcr.2014.11.020 Stoddard, 2015, Promising pharmacological directions in the world of lysophosphatidic acid signaling, Biomol Ther, 23, 1, 10.4062/biomolther.2014.109 Tager, 2008, The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak, Nat Med, 14, 45, 10.1038/nm1685 Leduc M, Tremblay M, Grouix B, Sarra-Bournet F, Felton A, Laurin P, et al. PBI-4050, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen I production in human alveolar epithelial cells and fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. A61 LUNG FIBROSIS: ANIMAL MODELS II: American Thoracic Society; 2014. p. A1998-A. Prometic. ProMetic’s PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial. Horan, 2008, Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation, Am J Respir Crit Care Med, 177, 56, 10.1164/rccm.200706-805OC Yu H, Lange C, Wille A, Siebers U, Rao E, Resnick R, et al. SAR156597, an IL4/IL13 Bi-specific MAb, possesses a unique MoA in inhibition of IL13 signaling. ICLAF 2014 18th International Colloquium on Lung and Airway Fibrosis Mont Tremblant, Quebec, Canada; 2014. p. 20-4. Jakubzick, 2003, Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4-and IL-13-responsive cells, J Immunol, 171, 2684, 10.4049/jimmunol.171.5.2684 Rao E, Li D, Underwood S, Mikol V, Davison M, Kruip J. Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis. MAbs2012. p. 14-6. Getsy JA, Harper D, Levy M, Burggraaf J, Moerland M, de Visser I, et al. The Effects Of Recombinant Human Pentraxin-2,(PRM-151), On Circulating Fibrocytes In Idiopathic Pulmonary Fibrosis (IPF). B102 INTERSTITIAL LUNG DISEASE: NOVEL MANAGEMENT AND OUTCOME STRATEGIES: American Thoracic Society; 2011. p. A3803-A. Murray, 2010, Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages, PLoS One, 5, e9683, 10.1371/journal.pone.0009683 Pilling, 2007, Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P, J Immunol, 179, 4035, 10.4049/jimmunol.179.6.4035 Funke, 2012, The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury, Am J Respir Cell Mol Biol, 46, 355, 10.1165/rcmb.2010-0155OC Van Der Aar, 2016, A103 IPF: MORE ABOUT THERAPY AND OUTCOMES: Favorable Human Safety, Pharmacokinetics And Pharmacodynamics Of The Autotaxin Inhibitor Glpg1690, A Potential New Treatment In Idiopathic Pulmonary Fibrosis, Am J Respir Crit Care Med, 193, 1 Yang, 2014, Activated alveolar epithelial cells initiate fibrosis through autocrine and paracrine secretion of connective tissue growth factor, Am J Physiol-Lung Cell Mol Physiol, 306, L786, 10.1152/ajplung.00243.2013 Lipson, 2012, CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis, Fibrogenesis tissue repair: BioMed Central, 1 Raghu, 2016, FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis, Eur Respir J, 47, 1481, 10.1183/13993003.01030-2015 MacKinnon, 2012, Regulation of transforming growth factor-β1–driven lung fibrosis by galectin-3, Am J Respir Crit Care Med, 185, 537, 10.1164/rccm.201106-0965OC Xie, 2015, Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis, Am J Respir Crit Care Med, 192, 1462, 10.1164/rccm.201504-0780OC Yin, 2019, Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-β, Sci Signal, 12, 10.1126/scisignal.aax4067 Cervantes-Madrid, 2015, Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy, Biomed Res Int, 2015, 10.1155/2015/690492 Hamanaka, 2018, Inhibition of phosphoglycerate dehydrogenase attenuates bleomycin-induced pulmonary fibrosis, Am J Respir Cell Mol Biol, 58, 585, 10.1165/rcmb.2017-0186OC Jung, 2018, Fatty acid synthase is required for profibrotic TGF-β signaling, FASEB J, 32, 3803, 10.1096/fj.201701187R Hecker, 2014, Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance, Sci Transl Med, 6, 10.1126/scitranslmed.3008182 Selvarajah, 2019, mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-β1–induced collagen biosynthesis, Sci Signal, 12, 10.1126/scisignal.aav3048 Sato, 2016, Metformin attenuates lung fibrosis development via NOX4 suppression, Respir Res, 17, 1, 10.1186/s12931-016-0420-x Bossuyt, 2003, The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration, Ann Intern Med, 138, W1, 10.7326/0003-4819-138-1-200301070-00012-w1 McShane, 2005, Reporting recommendations for tumor marker prognostic studies (REMARK), J Natl Cancer Inst, 97, 1180, 10.1093/jnci/dji237 Downing, 2001, Biomarkers definitions working group. Biomarkers and surrogate endpoints, Clin Pharmacol Ther, 69, 89, 10.1067/mcp.2001.113989 Fleming, 2012, Biomarkers and surrogate endpoints in clinical trials, Stat Med, 31, 2973, 10.1002/sim.5403